Related Experiment Video
Updated: Oct 9, 2026
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Effect of SM-12502 on disseminated intravascular coagulation (DIC) in tumor-bearing rats
Abstract:
To investigate the role of PAF in tumor-associated disseminated intravascular coagulation (DIC), we have established the tumor-induced DIC model in rats and examined the effect of PAF-antagonist as compared with commonly used anti-DIC drugs. Four days after the intraperitoneal inoculation of rat ascites hepatoma AH-130, DIC-like hematological parameter changes such as decrease in platelet count, prolongation of PTT and increase in FDP were observed. In addition, serum levels of GOT and GPT were increased, indicating that liver injury was provoked. PAF-antagonist SM-12502 inhibited the development of DIC (PT, PTT and FDP) and liver injury. These results indicate that PAF plays an important role in tumor-associated DIC as well as accompanying organ failure.
Insights
Platelet-activating factor (PAF) significantly contributes to tumor-associated disseminated intravascular coagulation (DIC) and liver injury in rats. PAF-antagonist SM-12502 effectively inhibited DIC development and organ damage, highlighting PAF
Area of Science:
- Biomedical research
- Hematology
- Oncology
Background:
- Disseminated intravascular coagulation (DIC) is a severe complication associated with various cancers.
- Tumor progression can trigger systemic inflammatory responses, leading to coagulation abnormalities.
- The precise mechanisms linking cancer to DIC, particularly the role of specific mediators, require further elucidation.
Purpose of the Study:
- To investigate the role of platelet-activating factor (PAF) in the pathogenesis of tumor-associated DIC.
- To evaluate the efficacy of a PAF-antagonist in a rat model of cancer-induced DIC.
- To compare the effects of a PAF-antagonist with conventional anti-DIC therapies.
Main Methods:
- Establishment of a rat model of ascites hepatoma (AH-130) to induce DIC.
- Monitoring of hematological parameters indicative of DIC, including platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrin degradation products (FDP).
- Assessment of liver injury through serum levels of aspartate aminotransferase (GOT) and alanine aminotransferase (GPT).
- Administration of PAF-antagonist SM-12502 and evaluation of its effects on DIC and liver injury markers.
Main Results:
- Tumor inoculation led to DIC-like changes: decreased platelet count, prolonged PT and aPTT, and elevated FDP levels.
- Significant increases in serum GOT and GPT indicated drug-induced liver injury.
- PAF-antagonist SM-12502 demonstrated significant inhibition of DIC development (PT, aPTT, FDP) and ameliorated liver injury.
- These findings suggest PAF is a key mediator in tumor-associated DIC and subsequent organ damage.
Conclusions:
- Platelet-activating factor (PAF) plays a critical role in the development of tumor-associated disseminated intravascular coagulation (DIC).
- PAF-antagonist SM-12502 effectively mitigates DIC and associated liver injury in a preclinical cancer model.
- Targeting PAF presents a potential therapeutic strategy for managing DIC and organ failure in cancer patients.
